Portal Vein Occlusion is a Valuable Predictor for Postoperative Nausea and Vomiting

NCT ID: NCT05894408

Last Updated: 2024-04-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

380 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-06-15

Study Completion Date

2023-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Postoperative nausea and vomiting (PONV) is one of the most common and distressing postoperative complications. PONV risk assessment is recommanded to determine the number of medications or strategies for prophylaxis. Many well-known risk factors have been determined. However, no study has explored liver surgery-specific risk factors. This study aims to identify whether there was an association between portal vein occlusion and PONV among patients after liver surgery. Patients diagnosed with liver cancer and undergoing hepatectomy will be prospectively consecutively recruited. All enrolled patients receive PONV assessments within the first 24 postoperative hours. Logistic regression models will be used to investigate the effects of portal vein occlusion and the other variables on the occurrence of PONV in both univariate and multivariate analyses

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Design This is a single-centre, prospective cohort study performed at a tertiary teaching hospital in Shanghai, China.
2. Participants We calculated the sample size based on the rule-of-thumb method from logistic modelling as follows: a minimum of 10 events per predictor variable should be achieved based on simulation studies. The reported incidence of PONV among patients undergoing general surgery ranged from 30% to 50%. We used the lowest incidence of 30% to estimate the sample size. The expected variable number included in the logistic model was 9, and adjusting for a 10% of loss to follow-up, the sample size was 330.

Patients will be prospectively consecutively recruited. Patients who are diagnosed with liver cancer and underwent hepatectomy are eligible. Inclusion criteria are age older than 18 years, planned admissions and elective surgery, and staying at least 24 hours in the surgical unit. We exclude patients with cognitive impairment and patients who had nausea and vomiting related to other existing diseases, such as gastroesophageal reflux disease. We also exclude patients who have severe postoperative complications, including massive abdominal hemorrhage, hepatic encephalopathy and portal vein thrombosis.
3. Setting The study will be conducted in the liver disease department in Zhongshan Hospital, Shanghai, China, which is the largest liver surgery department in eastern China. In 2018, the department performs nearly 3000 liver surgeries. The liver surgical department has 240 beds, and the department staff includes 106 nurses and physicians.
4. Data collection 4.1 Preoperative assessment All enrolled patients will receive preoperative assessments by trained investigators. The baseline demographic data and medical history will be recorded. We define smoking history as nicotine use before surgery, and history of motion sickness as nausea or vomiting when travelling in a car/boat/train/plane. Nonsmoking and history of motion sickness or PONV will be collected by interviewing patients and family members.

4.2 Postoperative assessment All enrolled patients receive postoperative assessments by trained nurses. The use of postoperative opioids and the length of surgery are determined by checking the hospital information system to review surgery records and anaesthetic protocols within 24 hours after surgery. The time of portal vein occlusion will be recorded by the surgeon.
5. Surgery and postoperative management A standard general anaesthesia technique is used for all patients. Different operations are performed according to the preoperative conditions of each patient. S
6. Outcome measures Postoperative nausea and vomiting will be assessed hourly during the first two hours, every two hours for the following four hours and every four hours until the 24th hour by the first and the second authors to ensure high-quality data collection. PONV will be evaluated on a four-grade scale from 0 (no nausea and no vomiting), 1 (having nausea but no vomiting), 2 (having vomiting without stomach contents ) to 3 (having vomiting with stomach contents). A patient will be considered to have PONV if his or her PONV grade is 2 or more within the first 24 postoperative hours. PONV will be assessed by the first author, who is blinded to the result of portal vein occlusion.
7. Statistical analysis Statistical analyses are conducted using IBM-SPSS software version 22 (IBM Corp., Armonk, NY, USA), Empower (R) (www.empowerstats.com, X\&Y solutions, Inc., Boston, MA), and R statistical software. Data are presented as the mean and standard deviation for continuous variables and as percentages for categorical variables. Normally distributed continuous variables are compared using one-way analysis of variance. The Pearson χ2 test is applied to all categorical variables. Logistic regression models are used to investigate the effects of portal vein occlusion and the other variables on the occurrence of PONV in both univariate and multivariate analyses. Independent variables are selected based on evidence from previous studies showing a significant relation to PONV and we also include other variables based on our clinical experience.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Nausea and Vomiting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients with portal vein occlusion

this is no intervention

Intervention Type OTHER

this is no intervention

patients without portal vein occlusion

this is no intervention

Intervention Type OTHER

this is no intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

this is no intervention

this is no intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* older than 18 years, planned admissions and elective surgery, and staying at least 24 hours in the surgical unit

Exclusion Criteria

* patients with cognitive impairment and patients who have nausea and vomiting related to other existing diseases, such as gastroesophageal reflux disease.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shanghai Zhongshan Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fudan University Fudan University

Shanghai, Shanghai Municipality, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

References

Explore related publications, articles, or registry entries linked to this study.

Chen X, Zhao WJ, Yu J, Zhou H, Shi Y, Gao J, Zhang Y. Duration of hepatic portal occlusion is a valuable predictor for postoperative nausea and vomiting in patients underwent liver resection for liver cancer. BMC Cancer. 2025 Jul 16;25(1):1177. doi: 10.1186/s12885-025-14592-0.

Reference Type DERIVED
PMID: 40670918 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SHDC22020204

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.